Tocagen Inc (NASDAQ:TOCA) – Analysts at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for shares of Tocagen in a research report issued on Thursday, October 17th. Cantor Fitzgerald analyst V. Kumar forecasts that the company will post earnings of ($2.91) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. Cantor Fitzgerald also issued estimates for Tocagen’s FY2020 earnings at ($2.59) EPS.
Tocagen (NASDAQ:TOCA) last announced its earnings results on Thursday, August 8th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.04. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million.
TOCA has been the subject of a number of other research reports. ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright cut Tocagen from a “buy” rating to a “neutral” rating and set a $3.32 target price for the company. in a report on Thursday, September 12th. Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Wednesday, September 18th. Citigroup cut Tocagen from a “buy” rating to a “neutral” rating and cut their price target for the company from $20.00 to $1.00 in a report on Friday, September 13th. Finally, Robert W. Baird cut Tocagen from an “outperform” rating to a “neutral” rating in a report on Thursday, September 12th. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $10.26.
Shares of Tocagen stock opened at $0.59 on Monday. The business has a 50 day simple moving average of $1.44 and a two-hundred day simple moving average of $5.48. Tocagen has a 12 month low of $0.53 and a 12 month high of $14.75. The stock has a market capitalization of $14.23 million, a P/E ratio of -0.24 and a beta of 3.90. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.21 and a quick ratio of 4.21.
A number of institutional investors have recently bought and sold shares of TOCA. Parametric Portfolio Associates LLC acquired a new stake in Tocagen in the second quarter valued at $75,000. A.R.T. Advisors LLC acquired a new stake in shares of Tocagen during the second quarter worth about $114,000. Dowling & Yahnke LLC increased its position in shares of Tocagen by 41.2% during the second quarter. Dowling & Yahnke LLC now owns 17,122 shares of the company’s stock worth $114,000 after purchasing an additional 5,000 shares in the last quarter. IPG Investment Advisors LLC acquired a new stake in shares of Tocagen during the second quarter worth about $134,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Tocagen by 8.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 50,940 shares of the company’s stock worth $341,000 after purchasing an additional 3,767 shares in the last quarter. Institutional investors own 35.38% of the company’s stock.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Article: Earnings Reports
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.